Xenon Joins the Russell 3000® and Russell 2000® Indexes
Xenon Pharmaceuticals (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company, has been added to the Russell 3000® and Russell 2000® Indexes as part of the annual reconstitution, effective June 27, 2025.
The Russell 3000® Index tracks the 3,000 largest U.S. stocks by market cap, while the Russell 2000® measures the 2,000 smallest companies within the Russell 3000®. These widely-used indexes serve as benchmarks for approximately $10.6 trillion in assets. The company's inclusion will result in automatic addition to corresponding growth and value style indexes.
Xenon Pharmaceuticals (Nasdaq: XENE), un'azienda biofarmaceutica specializzata in neuroscienze, è stata inserita nei Russell 3000® e Russell 2000® Indexes nell'ambito della ristrutturazione annuale, con effetto dal 27 giugno 2025.
Il Russell 3000® Index monitora le 3.000 maggiori azioni statunitensi per capitalizzazione di mercato, mentre il Russell 2000® misura le 2.000 società più piccole all'interno del Russell 3000®. Questi indici, ampiamente utilizzati, fungono da benchmark per circa 10,6 trilioni di dollari in asset. L'inclusione della società comporterà l'aggiunta automatica ai relativi indici di stile crescita e valore.
Xenon Pharmaceuticals (Nasdaq: XENE), una compañía biofarmacéutica enfocada en neurociencia, ha sido añadida a los Índices Russell 3000® y Russell 2000® como parte de la reconstitución anual, efectiva desde el 27 de junio de 2025.
El índice Russell 3000® rastrea las 3,000 mayores acciones de EE.UU. por capitalización de mercado, mientras que el Russell 2000® mide las 2,000 empresas más pequeñas dentro del Russell 3000®. Estos índices ampliamente utilizados sirven como referencia para aproximadamente $10.6 billones en activos. La inclusión de la compañía resultará en la adición automática a los índices correspondientes de estilo crecimiento y valor.
Xenon Pharmaceuticals (Nasdaq: XENE)는 신경과학에 중점을 둔 바이오제약 회사로서, 2025년 6월 27일부로 연례 재구성의 일환으로 Russell 3000® 및 Russell 2000® 지수에 편입되었습니다.
Russell 3000® 지수는 시가총액 기준 미국 최대 3,000개 주식을 추적하며, Russell 2000®은 Russell 3000® 내에서 가장 작은 2,000개 기업을 측정합니다. 이들 널리 사용되는 지수는 약 10.6조 달러의 자산에 대한 벤치마크 역할을 합니다. 회사의 편입으로 인해 해당 성장 및 가치 스타일 지수에도 자동으로 추가됩니다.
Xenon Pharmaceuticals (Nasdaq : XENE), une société biopharmaceutique axée sur les neurosciences, a été ajoutée aux indices Russell 3000® et Russell 2000® dans le cadre de la recomposition annuelle, effective à partir du 27 juin 2025.
L'indice Russell 3000® suit les 3 000 plus grandes actions américaines par capitalisation boursière, tandis que le Russell 2000® mesure les 2 000 plus petites entreprises au sein du Russell 3000®. Ces indices largement utilisés servent de référence pour environ 10,6 billions de dollars d'actifs. L'inclusion de la société entraînera son ajout automatique aux indices de style croissance et valeur correspondants.
Xenon Pharmaceuticals (Nasdaq: XENE), ein auf Neurowissenschaften fokussiertes biopharmazeutisches Unternehmen, wurde im Rahmen der jährlichen Neuzusammensetzung mit Wirkung zum 27. Juni 2025 in die Russell 3000® und Russell 2000® Indizes aufgenommen.
Der Russell 3000® Index verfolgt die 3.000 größten US-Aktien nach Marktkapitalisierung, während der Russell 2000® die 2.000 kleinsten Unternehmen innerhalb des Russell 3000® misst. Diese weit verbreiteten Indizes dienen als Benchmark für etwa 10,6 Billionen US-Dollar an Vermögenswerten. Die Aufnahme des Unternehmens führt zur automatischen Hinzufügung in die entsprechenden Wachstums- und Value-Stilindizes.
- Inclusion in Russell 3000® and Russell 2000® Indexes increases visibility to institutional investors
- Potential for increased trading volume and liquidity due to index fund inclusion
- Access to broader investor base through automatic inclusion in growth and value style indexes
- None.
Insights
Xenon's inclusion in Russell indexes brings increased visibility, potential passive investment flows, and enhanced institutional credibility.
Xenon Pharmaceuticals' addition to the Russell 3000® and Russell 2000® Indexes represents a significant milestone that carries several tangible benefits for the company and its shareholders. With approximately
This development will likely trigger mandatory buying from index funds that must replicate the Russell indexes' composition. Beyond the immediate price support this creates, the inclusion provides enhanced visibility among institutional investors and fund managers who use these benchmarks as their investment universe. For a neuroscience-focused biopharmaceutical company like Xenon, this institutional validation comes at a strategically important time as they advance their ion channel product portfolio.
The company's lead candidate, azetukalner (a Kv7 potassium channel opener), is described as being in late-stage clinical development for multiple indications including epilepsy and depression - areas with substantial market potential. The Russell inclusion adds a layer of financial credibility that complements their scientific progress, potentially making it easier to attract capital for their clinical development programs.
This index addition reflects Xenon's growth in market capitalization and liquidity requirements necessary to meet Russell inclusion criteria, signaling the market's recognition of the company's progress in their neuroscience pipeline development.
VANCOUVER, British Columbia and BOSTON, June 27, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced that the company has been added to the broad-market Russell 3000® and small-cap Russell 2000® Indexes as part of the annual reconstitution, effective at the close of U.S. equity markets on Friday, June 27, 2025.
The Russell 3000® Index is an equity index that tracks the performance of the largest 3,000 U.S. stocks by market capitalization. The Russell 2000® Index measures the performance of the 2,000 smallest companies within the Russell 3000® Index. Inclusion in the Russell 2000® results in automatic inclusion in the appropriate growth and value style indexes.
Russell U.S. Indexes are widely used by investment managers and institutional investors as the basis for index funds and as benchmarks for investment strategies. Approximately
For more information on the Russell 3000® Index and the Russell indexes reconstitution, go to the “Russell Reconstitution” section on the FTSE Russell website.
About Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals (Nasdaq: XENE) is a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics. We are advancing an ion channel product portfolio to address areas of high unmet medical need, including epilepsy and depression. Azetukalner, a novel, highly potent, selective Kv7 potassium channel opener, represents the most advanced, clinically validated potassium channel modulator in late-stage clinical development for multiple indications. For more information, please visit www.xenon-pharma.com.
“Xenon” and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in various jurisdictions. All other trademarks belong to their respective owner.
Contacts:
For Investors:
Chad Fugere
Vice President, Investor Relations
(857) 675-7275
investors@xenon-pharma.com
For Media:
Colleen Alabiso
Senior Vice President, Corporate Affairs
(617) 671-9238
media@xenon-pharma.com
FAQ
What does Xenon's inclusion in the Russell indexes mean for XENE stock?
When will XENE stock be added to the Russell 2000 index?
What is Xenon Pharmaceuticals' main business focus?
How many stocks are tracked in the Russell 3000 Index?
